drugset / Trial / NCT04834089
Clinical Trial for Assessment of Anti-SARS-CoV-2 Serum for Early Treatment of COVID-19 Cases
RandomizedParallel-groupDouble-blindTreatment
Summary
Phase I/II Randomized Clinical Trial to evaluate the safety, pharmacokinetic and efficacy of Anti-SARS-CoV-2 hyperimmune serum. The study will include patients at early stage of COVID-19 with increased risk for severe disease due to underlying medical conditions to determine the utility of an equine heterologous serum anti-SARS-CoV-2 to avoid progression to a severe COVID-19
Timeline
- Start
- 2021-05
- Primary completion
- 2022-05
- Completion
- 2022-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AntiSARS-CoV-2 Serum | Protein / enzyme biologic | 5 ml | Intravenous |
| Subject | AntiSARS-CoV-2 Serum | Protein / enzyme biologic | 10 ml | Intravenous |